Ryvu Therapeutics SA - ESG Rating & Company Profile powered by AI
Comprehensive ESG analysis of Ryvu Therapeutics SA are accessed by signing in. If you work at Ryvu Therapeutics SA and you wish to use your ESG rating, please get in touch. Jump to the end of the page for potential risks for Ryvu Therapeutics SA based on industry, location and size.
Ryvu Therapeutics SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.5; made up of an environmental score of 8.0, social score of 8.0 and governance score of 3.4.
6.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 483 | Provention Bio Inc | 6.6 | High |
| 483 | PuraPharm Corp Ltd | 6.6 | High |
| 511 | Ryvu Therapeutics SA | 6.5 | High |
| 511 | BPH Energy Ltd | 6.5 | High |
| 511 | Abcam PLC | 6.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Ryvu Therapeutics SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Ryvu Therapeutics SA report the average age of the workforce?
Sign up for free to unlockDoes Ryvu Therapeutics SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose cybersecurity risks?
Sign up for free to unlockDoes Ryvu Therapeutics SA offer flexible work?
Sign up for free to unlockDoes Ryvu Therapeutics SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Ryvu Therapeutics SA conduct supply chain audits?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Ryvu Therapeutics SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose water use targets?
Sign up for free to unlockDoes Ryvu Therapeutics SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Ryvu Therapeutics SA have a product recall in the last two years?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose incidents of discrimination?
Sign up for free to unlockDoes Ryvu Therapeutics SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Ryvu Therapeutics SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose parental leave metrics?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Ryvu Therapeutics SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Ryvu Therapeutics SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Ryvu Therapeutics SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose its waste policy?
Sign up for free to unlockDoes Ryvu Therapeutics SA report according to TCFD requirements?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose energy use targets?
Sign up for free to unlockDoes Ryvu Therapeutics SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Ryvu Therapeutics SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Ryvu Therapeutics SA
These potential risks are based on the size, segment and geographies of the company.
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.